H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s supplemental update to its Phase 1 CTX310 trial findings, H.C. Wainwright reaffirmed its Buy rating and $65 price target on the company on June 27.

H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update

Pixabay/Public Domain

According to the latest results, CTX310, an in vivo ANGPTL3 knockout therapy, continues to exhibit peak reductions of up to 82% in triglycerides and around 86% in LDL cholesterol at dose level four. These reductions were made without causing any discernible alterations in liver enzyme levels, preserving a safety profile in line with previous research.

However, H.C. Wainwright pointed out that baseline cholesterol control measurements, the existence of only one patient at the highest dose level, and illness variability continue to limit analysis. Future updates, including disease-specific efficacy data, response levels over time, and reduced error values, would be of interest to the firm.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.